CAMBRIDGE, UK, and LEUVEN, Belgium, 13 January 2020 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has partnered with imec, a world-leading research and innovation hub active in the fields of nanoelectronics and digital technologies, to increase production of Evonetix’s proprietary microelectromechanical systems (MEMS)-based silicon chips, enabling the platform to be manufactured at a commercial scale. The novel silicon chip is a key component of Evonetix’s desktop DNA platform…
Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology
Product designed to provide safer, more immediate treatment option for patients
London and Cambridge, January 9, 2020 - Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into an exclusive agreement to co-…
08 January 2020, London, UK: Optimum Strategic Communications (Optimum), the international strategic healthcare communications firm, today announced the appointment of Shabnam Bashir. Shabnam brings 10 years of experience advising UK and international companies ranging from start-ups to large public organisations across a range of sectors advising on strategy, crises management, IPO and M&A transactions.
Shabnam joins from Citigate Dewe Rogerson (part of Huntsworth Health), where she applied her broad-based experience to support the Life sciences and Healthcare team. In her role at…
J A Kemp LLP has appointed Dr Ian MacLeod as a Partner in its London office.
Ian is qualified as a European and UK Chartered Patent Attorney. He joined J A Kemp in January 2020 after working for over ten years at another top tier firm. [Carpmaels & Ransford]
Ian handles a wide range of subject matter in the biotechnological and life sciences field, with particular expertise in bacterial products targeting the microbiome, vaccines, antibody therapeutics, biomarker diagnostics, and antisense nucleotides.
Ian has extensive experience of drafting patents and of prosecuting and defending…
Cambridge, UK, 07 January: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is pleased to confirm that its PROFILE trial has reached the half way mark in terms of recruitment, having secured over 200 patients.
Funded by Wellcome Trust as part of its translational grant award funding stream, the PROFILE trial is the first biomarker stratified study for Crohn’s disease and potentially immune-mediated diseases as a whole. The trial seeks to demonstrate that stratifying…
DUBLIN, Ireland, and Ipswich MA, USA, 07 January 2020: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with New England Biolabs (NEB®), a global leader in the discovery and production of enzymes for molecular biology applications, granting NEB rights to sell CRISPR/Cas9 tools and reagents.
NEB offers the largest selection of recombinant and native enzymes for genomic research, and continues to expand its product offerings into new areas…
Cambridge, UK, 07 January 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments. Under the terms of the agreement, PhoreMost will receive an upfront payment and research funding together with downstream success-based milestones. Further financial terms are not disclosed.
PhoreMost will deploy its in-…
Cambridge 06 January 2020: Sponsors of the Babraham Research Campus Accelerate@Babraham initiative, LifeArc, has announced the extension of its support, by releasing an additional £10,000 in the form of an award for the most progressed venture currently participating in the StartUPCompetition@Babraham 2019/20 programme.
Introduced by the Babraham Research Campus in 2018, the Accelerate@Babraham initiative is designed to support ambitious early stage life science ventures within the active Babraham Research Campus community. It does this by giving access to appropriate short-term open…
Viral vectors have taken a striking importance in the current biomanufacturing landscape, with the unprecedented global need for viral particles creating significant capacity and productivity challenges.
Join our educational webinar and learn how recent innovation can help you to significantly push the boundaries of viral vectors productivity and quality.
Discover how recent innovation in areas such as cells, media and transfection agents can boost and standardise your process, as illustrated by our lentiviral case study. Get updates about recent innovations in both benchtop and production…
AMSBIO has expanded its range of cfPure™ Cell Free DNA Purification Kits for rapid and efficient isolation of circulating cell free DNA (cfDNA). A new cfPure™Max kit is now available for use on samples of 5mLs volume or greater.AMSBIO cfPure® kits use silica-coated paramagnetic particles to purify cell free DNA from less than 1 mL to greater than 10 mL of serum or plasma. The buffers were developed to ensure efficient recovery of 100 bp – 500 bp DNA fragments in order to maximize recovery of cell free DNA. The recovered DNA is suitable for a wide range of down-…